The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Recurrence-free survival (RFS) and objective response rate (ORR) phase 1/2 study of intralesional (IL) neoadjuvant (neo) anti-PD1 agents (aPD1) for stage IIIB-IV melanoma (MEL).
 
Igor Samoylenko
Speakers' Bureau - Bristol-Myers Squibb; Merck/Schering Plough; Novartis; R-Farm
Research Funding - Novartis
 
Olga V. Korotkova
No Relationships to Disclose
 
Ekaterina Shakhray
No Relationships to Disclose
 
Tatiana Zabotina
No Relationships to Disclose
 
Sergey Berdnikov
No Relationships to Disclose
 
Dmitry Tabakov
No Relationships to Disclose
 
Elena Zakharova
No Relationships to Disclose
 
Natalia N. Petenko
No Relationships to Disclose
 
Lev V. Demidov
Speakers' Bureau - BioCad; Bristol-Myers Squibb; Merck/Schering Plough; Novartis; Roche